대한뉴팜

In January 2017, Daehan New Pharm launched “Pleincell,” a hyaluronic acid (HA) filler containing lidocaine. The name “Pleincell,” derived from the French word meaning “to be full,” represents the product’s ability to deliver natural volume. It features a patented cross-linking technology that creates a uniform HA particle structure, while its low residual BDDE content minimizes toxicity. Additionally, it is completely dissolvable with hyaluronidase, ensuring excellent safety and reversibility. A filler is a medical device that restores skin tissue volume and improves wrinkles or facial contours through injection beneath the skin. A variety of fillers are currently available, including those based on HA, PLA, and PCA. The HA filler market alone has surpassed 100 billion KRW and continues to grow by more than 10% annually. Leveraging its strong brand recognition in wellness and beauty pharmaceuticals, Daehan New Pharm is actively reviewing the introduction of diverse facial aesthetic treatments and medical devices to expand its presence in this high-growth segment.

Executive Director Jeong Jin-tae Leads New Forage Business Initiative Pursuing a New Forage Business to Create a Growth EngineClose Field Engagement – Maximizing Synergy with Existing Animal Health Business After completing a 30-year career with the National Agricultural Cooperative Federation (NACF), Executive Director Jeong Jin-tae began a new chapter at Daehan New Pharm on the 1st of last month. “I may have left the cooperative, but its spirit still runs through me,” Jeong said, expressing his commitment to continue contributing to the livestock industry and supporting livestock farmers through his role at Daehan New Pharm. He added, “Customer growth is company growth. With a mindset that consumers and businesses are one, we aim to build a business model of mutual prosperity.” Jeong explained that Daehan New Pharm is now advancing into the forage business as a new growth initiative.“I was in charge of forage operations for quite a long time at the NACF. With that experience and know-how, I’m confident that the forage business can thrive here as well. We’re already seeing tangible results, including initial sales,” he said, while emphasizing that profitability alone is not the goal. “Our aim is to supply high-quality forage at reasonable prices to enhance the productivity of livestock farmers and ease their production cost burden,” Jeong noted.He added, “For Daehan New Pharm, this means providing more diversified customer services. The forage business will not only become a new growth engine but also generate synergy with our existing animal pharmaceutical operations.” Jeong underscored his field-oriented approach: “I visit farms daily and listen directly to what they need. Later this month, I will travel to Australia to identify better forage products that meet farmers’ demands. There, I plan to carefully assess quality and pricing to ensure competitiveness.” Having embarked on what he calls his “second life chapter” at Daehan New Pharm, Jeong admitted that adapting to the corporate business culture was initially unfamiliar but quickly became meaningful.“I’ve fully adjusted and now have a clear goal—to devote all my remaining passion and ability to elevating Daehan New Pharm into Korea’s leading animal pharmaceutical company,” he said with conviction. Reported by Kim Young-gil, Livestock Cooperative NewsOriginal article: http://www.chuksannews.co.kr/news/article.html?no=104640

- Achieved cumulative Q3 sales of 79.7 billion KRW and operating profit of 8.6 billion KRW, representing over 20% year-on-year growth- Sustained strong performance across all major business sectors, including pharmaceuticals, wellness, and veterinary medicine- “We expect to maintain this growth momentum into Q4, targeting annual sales of 110 billion KRW and operating profit of 12 billion KRW” Daehan New Pharm continued its double-digit growth for the 17th consecutive quarter, maintaining an average sales increase of around 20%. According to consolidated results for the third quarter, the company reported cumulative sales of 79.7 billion KRW and operating profit of 8.6 billion KRW. Compared to the same period last year, sales rose by 19.1% and operating profit by 17.4%, marking the 17th consecutive quarter of double-digit growth since Q3 2012—a record of consistent performance that holds strong significance. This consistent growth stems from balanced expansion across all business divisions. The pharmaceutical division has strengthened market dominance through differentiated business models such as lyophilized injectable development, cutting-edge clinical protocols, and customized solution-based sales strategies. The wellness division also played a key role by successfully leading new product initiatives and expanding its portfolio. In the veterinary medicine division, despite sluggish market conditions, Daehan New Pharm achieved approximately 10% year-on-year sales growth through customer-centered product development and on-site engagement, breaking the notion that the market has reached maturity and limited growth potential. Within the human pharmaceutical portfolio, new products such as Newtor Tab.—a cardiovascular therapy—and New-DN Injection., an injectable used for post-skin graft wound care, have gained robust market traction. These new products now account for over 30% of total sales, further strengthening the company’s overall product portfolio. Daehan New Pharm CEO Bae Gun-woo commented, “In our international operations, we are reinforcing partnerships with key markets such as Russia and China to achieve our global business objectives. We are also actively expanding into new markets including Mongolia and Australia, further building on the capabilities that earned us the ‘10 Million Dollar Export Tower’ award last year.” He added, “Our sustained growth has been driven by differentiated solution development, creative sales strategies, and strong human capital. We are confident of reaching 110 billion KRW in annual sales and 12 billion KRW in operating profit in 2016. Looking ahead, we will continue this growth trajectory by strengthening R&D for improved pharmaceuticals, developing new growth engines in the bio and global sectors, and enhancing the core competencies of our key talent.”

Last month, Daehan New Pharm's CEO Bae Gun-woo, Overseas Business Director Kim Young-dong, and the Mongolian exclusive distributor partner City Medlux appeared on a segment called "Let's Have a Cup of Tea," a morning program on Mongolia's UBS broadcast. They introduced three products: Luthione Injection, Cindella Injection, and Vitamin C Injection. Daehan New Pharm signed an exclusive supply agreement with Mongolia’s City Medlux LLC for these three products and completed pharmaceutical registration last month, planning to conduct active marketing and sales efforts.This broadcast is expected to enhance Daehan New Pharm’s reputation and contribute to increasing sales in the Mongolian market. The company also plans to gradually expand from pharmaceuticals to medical devices and cosmetics with products such as Liporase, Mesocartin, fillers, and Luthione cosmetics.

Daehan New Pharm participated as an exhibitor at the International Beauty Expo (CIBE) held in Guangzhou, China, from September 4th to 6th, 2016, to promote its Luthione cosmetics line. The International Beauty Expo is Asia's largest cosmetics and beauty professional exhibition, featuring over 3,800 companies from 26 countries. At the event, Daehan New Pharm showcased seven Luthione cosmetics products, including skin toner, lotion, cream, eye cream, and mask packs, along with medical devices, receiving significantly higher interest than expected. Luthione cosmetics differentiate themselves from typical products by using cucumber extracts instead of purified water commonly found in cosmetics. Adhering to a “10-Free” policy, the products minimize chemical ingredients by excluding parabens, artificial colors, surfactants, benzyl alcohol, artificial fragrances, and more. Instead, the formula includes eight types of vitamins to maximize skin nutrition. Moreover, the inclusion of glutathione and a luminous network formula enhances whitening and radiant skin effects. The Luthione brand was already well recognized among Chinese tourists (Youkers) visiting for beauty treatments, known for its skin whitening injection. Leveraging this brand recognition, Daehan New Pharm expanded into the cosmetics field with Luthione and plans to actively market the brand to ensure successful establishment in the Chinese market.

An export contract was signed with Vellesshima Medical, located in Tokyo, for PPC formulation medicine (product name: Ripolysis) at a scale of 3,000 vials per month. Daehan New Pharm has been regularly exporting 10,000 vials per month of 50ml Vitamin C to Japan since 2011. Although entering the Japanese market is initially challenging, once established, it allows for long-term and stable supply without price constraints. Daehan New Pharm plans to successfully launch Lipolysis, develop additional products, and actively expand into the Japanese market. Since receiving the $10 million Export Tower award in 2015, the company has been more actively promoting overseas exports. It is strengthening partnerships in strategic overseas bases such as Russia and vigorously expanding into new markets. Well-being products inspired by the Korean Wave have shown good responses in China and Southeast Asia, leading to active overseas market development.

Daehan New Pharm launched New-DN Injection, containing Polydeoxyribonucleotide (known as "salmon injection ingredient"), in April. The product was developed primarily by Korea BMI and is jointly marketed by Daehan New Pharm and two other companies. Within one week of launch, the initial batch of orders was fully distributed to the market, including wholesalers and clinics, with the second batch already awaiting supply, indicating a successful release and expected significant contribution to sales. The overall market for salmon injection ingredients is currently estimated to be around 40 billion KRW but is predicted to exceed 50 billion KRW in 2016 due to the increasing number of companies selling these products. New-DN Injection, well known for its salmon injection ingredient, has primarily been used as an adjunct therapy for pain relief in anesthesiology and orthopedics. Due to its tissue regeneration effects, it is also used in the skin and beauty sectors in combination with HA fillers, known as “water glow injections.” Daehan New Pharm is already well recognized in the skin beauty area with products like Luthione Injection and Cindella Injection. Unlike other co-marketing partners, Daehan New Pharm holds confidence that it can lead and expand the therapeutic market for salmon injection ingredients. Current sales data show that about 50% of New-DN Injection’s client base comes from dermatology. The company plans to achieve sales of over 3 billion KRW for New-DN Injection in 2016 and aims to reach 10 billion KRW in 2017. Leveraging its experience from New-DN Injection, Luthione Injection, and Cindella Injection, Daehan New Pharm plans to expand further into the skin beauty business, including fillers and beauty devices.

Daehan New Pharm, listed on KOSDAQ (054670), posted first-quarter 2016 results with sales growing 15.1% year-over-year to 24.086 billion KRW and operating profit increasing 15.2% to 2.604 billion KRW, maintaining a high-growth trend for the fourth consecutive year. The company’s strategy focuses on expanding its product portfolio, strengthening customer relationships through creative solution-based sales, overcoming limits with proactive management, and continuously creating value innovation centered on talent management while concentrating on core activities.

Daehan New Pharm’s export pharmaceutical product, Trimedat, which received the $10 million Export Tower award in 2015, was honored at the Russian Pharma Awards. This award ceremony is one of the most important events in the Russian pharmaceutical industry, with over 4,000 doctors voting directly to determine the winning medicines. The award signifies that Trimedat tablets are recognized as a reliable and excellent product in the Russian market. This achievement was made possible through close collaboration with Russian partners over more than ten years. In 2015, Trimedat recorded sales of $2.3 million, with a target of $3.5 million for the current year. To increase exports to Russia, Daehan New Pharm is in the process of registering one injectable product, one antibiotic, and one oral medication. Upon completion of these three registrations, the company expects to achieve export sales of $10 million solely from the Russian market. To sustain export growth, Daehan New Pharm is strategically focusing on Russia, China, and Southeast Asia as export bases, while also developing new markets in untapped regions such as Cuba, and expanding in growing markets like Pakistan, Azerbaijan, and Mongolia. Additionally, the company is concentrating its efforts on exporting veterinary pharmaceuticals to Middle Eastern markets. Currently, Daehan New Pharm has established a worldwide network through strategic partnerships in over 20 countries and more than 60 alliances globally.